Format

Send to

Choose Destination
Blood. 2017 Jan 19;129(3):383-385. doi: 10.1182/blood-2016-06-720599. Epub 2016 Nov 22.

A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma.

Author information

1
Clinical Division of Oncology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.
2
Department of Internal Medicine V, Hematology and Oncology, Medical University of Innsbruck, Innsbruck, Austria.
3
IIIrd Medical Department with Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectious Diseases, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria.
4
Salzburg Cancer Research Institute, Salzburg, Austria.
5
Clinical Division of Hematology, Department of Medicine, Medical University of Graz, Graz, Austria.
6
Center for Hematology and Medical Oncology, Department of Internal Medicine III, Allgemeines Krankenhaus Linz, Linz, Austria; and.
7
Department of Radiology and.
8
Department of Clinical Pathology, Medical University Vienna, Vienna, Austria.
PMID:
27879257
DOI:
10.1182/blood-2016-06-720599
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center